Recommanded Product: 329-59-9In 2011 ,《A novel potential therapeutic avenue for autism: Design, synthesis and pharmacophore generation of SSRIs with dual action》 was published in Bioorganic & Medicinal Chemistry Letters. The article was written by Ghoneim, Ola M.; Ibrahim, Diaa A.; El-Deeb, Ibrahim M.; Lee, So Ha; Booth, Raymond G.. The article contains the following contents:
Autism symptoms are currently modulated by Selective Serotonin Reuptake Inhibitors (SSRIs). SSRIs slow onset of action limits their efficiency. The established synergistic activity of SSRIs and 5HT1B/1D autoreceptors antagonists motivated us to incorporate SSRIs and 5HT1B/1D antagonists in one hybrid’ mol. A library of virtual hybrid’ mols. was designed using the tethering technique. A pharmacophore model was generated derived from 16 structurally diverse SSRIs (K i = 0.013-5000 nM) and used as 3D query. Compounds with fit values (≥2) were chosen for synthesis and subsequent in vitro biol. evaluation. Our pharmacophore model is a promising milestone to a class of SSRIs with dual action. In the experiment, the researchers used Methyl 4-fluoro-3-nitrobenzoate(cas: 329-59-9Recommanded Product: 329-59-9)
Methyl 4-fluoro-3-nitrobenzoate(cas: 329-59-9) belongs to methyl benzoate. Methyl benzoate reacts at both the ring and the ester, depending on the substrate. Electrophiles attack the ring, illustrated by acid-catalysed nitration with nitric acid to give methyl 3-nitrobenzoate.Recommanded Product: 329-59-9
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics